Ranbaxy expedited HIV generics
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Ranbaxy will begin filing its full range of generic antiretroviral HIV drugs before the end of 2004 under the Emergency Plan for AIDS Relief, the firm says Aug. 2. The $15 bil. Bush Administration plan, announced in May, provides for an expedited review process; a draft guidance on fixed-dose combination and co-packaged HIV/AIDS drugs sets a formal six-month review period, but FDA's goal is to review combo products in six weeks...
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.